A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)
作者: Fiona SimpkinsRichard DrakePedro F. EscobarBenjamin NutterNabila RasoolPeter G. Rose
作者单位: 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, United States
2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, OH, United States
3Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, United States
刊名: Gynecologic Oncology, 2015, Vol.136 (2), pp.240-245
来源数据库: Elsevier Journal
DOI: 10.1016/j.ygyno.2014.12.004
关键词: Advanced stage endometrial cancerChemotherapyBevacizumab
原始语种摘要: Abstract(#br)Objective(#br)To evaluate the effect of adding bevacizumab to adjuvant paclitaxel and carboplatin and as maintenance on progression-free survival (PFS) in advanced or recurrent endometrial carcinoma (EMCA).(#br)Methods(#br)A phase II trial was conducted in patients with measurable disease. Paclitaxel (175mg/m 2 /3h), carboplatin (AUC 5) and bevacizumab (15mg/kg) were administered q 21 days. Patients with a complete response after 6–8cycles received maintenance therapy with bevacizumab 15mg/kg q 21 days for 16cycles. Based on GOG 177 which had a 6-month PFS rate of 59%, an increase in 6-month PFS to 72% with the treatment regimen was considered of clinical...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:3.929 (2012)

×